Yang Lijun, Kress Benjamin T, Weber Harris J, Thiyagarajan Meenakshisundaram, Wang Baozhi, Deane Rashid, Benveniste Helene, Iliff Jeffrey J, Nedergaard Maiken
J Transl Med. 2013 May 1;11:107. doi: 10.1186/1479-5876-11-107.
Neurodegenerative diseases such as Alzheimer's are associated with the aggregation of endogenous peptides and proteins that contribute to neuronal dysfunction and loss. The glymphatic system, a brain-wide perivascular pathway along which cerebrospinal fluid (CSF) and interstitial fluid (ISF) rapidly exchange, has recently been identified as a key contributor to the clearance of interstitial solutes from the brain, including amyloid β. These findings suggest that measuring changes in glymphatic pathway function may be an important prognostic for evaluating neurodegenerative disease susceptibility or progression. However, no clinically acceptable approach to evaluate glymphatic pathway function in humans has yet been developed.
Time-sequenced ex vivo fluorescence imaging of coronal rat and mouse brain slices was performed at 30-180 min following intrathecal infusion of CSF tracer (Texas Red- dextran-3, MW 3 kD; FITC- dextran-500, MW 500 kD) into the cisterna magna or lumbar spine. Tracer influx into different brain regions (cortex, white matter, subcortical structures, and hippocampus) in rat was quantified to map the movement of CSF tracer following infusion along both routes, and to determine whether glymphatic pathway function could be evaluated after lumbar intrathecal infusion.
Following lumbar intrathecal infusions, small molecular weight TR-d3 entered the brain along perivascular pathways and exchanged broadly with the brain ISF, consistent with the initial characterization of the glymphatic pathway in mice. Large molecular weight FITC-d500 remained confined to the perivascular spaces. Lumbar intrathecal infusions exhibited a reduced and delayed peak parenchymal fluorescence intensity compared to intracisternal infusions.
Lumbar intrathecal contrast delivery is a clinically useful approach that could be used in conjunction with dynamic contrast enhanced MRI nuclear imaging to assess glymphatic pathway function in humans.
阿尔茨海默病等神经退行性疾病与内源性肽和蛋白质的聚集有关,这些聚集会导致神经元功能障碍和丧失。最近发现,脑淋巴系统是一种全脑范围的血管周围途径,脑脊液(CSF)和间质液(ISF)沿此途径快速交换,它是从大脑清除间质溶质(包括β淀粉样蛋白)的关键因素。这些发现表明,测量脑淋巴途径功能的变化可能是评估神经退行性疾病易感性或进展的重要预后指标。然而,目前尚未开发出临床上可接受的评估人类脑淋巴途径功能的方法。
在将脑脊液示踪剂(Texas Red-葡聚糖-3,分子量3 kD;异硫氰酸荧光素-葡聚糖-500,分子量500 kD)鞘内注入大鼠和小鼠的小脑延髓池或腰椎后30 - 180分钟,对冠状位大鼠和小鼠脑切片进行时间序列离体荧光成像。对大鼠不同脑区(皮质、白质、皮质下结构和海马体)的示踪剂流入量进行定量,以描绘注入后沿两条途径的脑脊液示踪剂的移动情况,并确定鞘内注入腰椎后是否可以评估脑淋巴途径功能。
鞘内注入腰椎后,小分子量的TR-d3沿血管周围途径进入大脑,并与脑间质液广泛交换,这与小鼠脑淋巴途径的最初特征一致。大分子量的FITC-d500仍局限于血管周围间隙。与小脑延髓池注入相比,鞘内注入腰椎后实质荧光强度峰值降低且延迟。
鞘内注入腰椎造影剂是一种临床上有用的方法,可与动态对比增强MRI核成像结合使用,以评估人类的脑淋巴途径功能。